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LETTER TO THE EDITOR
Combination treatment with metronomic
temozolomide, bevacizumab and
long-acting octreotide for malignant
neuroendocrine tumours
Dear Editor
Neuroendocrine tumours (NETs) are highly vascu-
larised tumours that express high levels of the vascular
endothelial growth factor (VEGF) ligand together with
its receptor VEGFR (Modlin et al. 2008). Although
advanced NETs may exhibit a 30–40% response rate to
combination chemotherapeutic approaches, the
response to single-agent chemotherapy is only 10%
(Modlin et al. 2008). Bevacizumab (BVZ; Avastin,
Roche, Basle, Switzerland), an anti-VEGF humanised
monoclonal antibody, has been shown to exert
objective tumour responses and improvement in
median time to progression (TTP) in advanced
carcinoid tumours (Yao et al. 2008). Additionally, a
recently published study reported that temozolomide
(TMZ), an oral chemotherapy derivative of dacarba-
zine, at a dose of 200 mg/m
2 on ﬁrst 5 days of each
28-day cycle may exert a signiﬁcant effect on NETs
(Ekeblad et al. 2007). A previous report that examined
a variety of NETs suggested that the combination of
BVZ and TMZ can be safely administered and shows
promising activity in patients who had failed to prior
treatments (Kulke et al. 2006a). Additionally, there is
growing interest on regimens that introduce continuous
low-dose TMZ administration as protracted low-dose
TMZ regimens may deplete O6-methylguanine DNA
methyltransferase (MGMT), an important factor in
cases of TMZ resistance and/or inhibit endothelial cell
proliferation and formation of tumour vasculature via
the so-called metronomic effect (Tolcher et al. 2003,
Lam et al. 2007). Although the exact mechanism of
action of somatostatin analogues is not well under-
stood, a long-standing hypothesis based on preclinical
experiments suggests that they exert an antiangiogenic
effect (Grozinsky-Glasberg et al. 2008).
Given the high degree of endothelial proliferation,
high vascular permeability and high expression of pro-
angiogenic growth factors such as VEGF in NETs,
angiogenesis inhibition by multiple pathways may be a
rational treatment strategy for these tumours. We
conductedapilotstudytoassessthetoxicityandefﬁcacy
of a combination antiangiogenic regimen including a
metronomic TMZ schedule, BVZ and octreotide in a
cohort of patients with a variety of advanced NETs that
had progressed on previous therapies.
FromJanuary2007untilJanuary2009,15patientswith
advanced NETs, mainly grade II tumours with Ki-67
labelling index (LI) 3–19%, were treated with com-
bination treatment including oral TMZ (Temodal, MSD,
Geneva, Switzerland) at a continuous standard daily dose
of 100 mg before bedtime, BVZ 7.5 mg/m
2 every
3 weeks i.v. and 30 mg of the somatostatin analogue,
octreotide long-acting release (Sandostatin 30 mg LAR;
Novartis, Basle, Switzerland) i.m. every 4 weeks. The
study was approved by the Institutional Review Board
and Ethics Committee at each participating centre and
wasconductedinaccordance withGoodClinicalPractice
principles and applicable local regulations. All patients
provided written informed consent. The cycle duration
was considered to be 3 weeks based on the BVZ infusion.
After a median of 18 months of follow-up, data were
analysed for toxicity, chromogranin A (CgA) percentage
variations, best radiological response and TTP. Adverse
eventswereevaluatedaccordingtotheCommonToxicity
Criteria,version3.0oftheNationalCancerInstitute.CgA
(normal value 12–98 ng/ml) levels were evaluated before
theﬁrstcycleandeverytwocycles,whereasimagingwith
triple-phase computed tomography or magnetic reso-
nance imaging was performed every four cycles.
Radiological response was classiﬁed according to
Response Evaluation Criteria in Solid Tumours version
1.1 (Eisenhauer et al. 2009) .T T Pw a sd e ﬁ n e da st h et i m e
from treatment initiation until radiological tumour
progression.Theextentofdisease,basedontheAmerican
Joint Committee on Cancer Staging Manual, 7th edition,
and the grading of the tumours based on the recent WHO
classiﬁcation(Bosmanetal.2010)wererecordedforeach
patient and assessed centrally by the same radiologist and
pathologist with a special interest in NETs.
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gressed after at least one regimen of chemotherapy,
were enrolled over a 2-year period in two participating
centres in this study of a combined treatment schedule
including TMZ, BVZ and a somatostatin analogue
(temozolomide, bevacizumab & somatostatin
analogue; TeBeSa). Patients had a median age of
62.5 (range 47–78) years and received a median
number of 12 (range 4–20) cycles. Patient charac-
teristics including demographics and previous treat-
ments are shown in Table 1.
Toxicity was observed in six out of 15 (40%)
patients and included one patient with Grade III
vomiting 2 h following ingestion of the ﬁrst TMZ
capsule regardless of the co-administration of meto-
clopramide 20mg orally. Two patients developed grade
I neutropenia that required discontinuation of TMZ
capsules for 1 week. One patient developed Grade II
thrombocytopenia, and TMZ treatment was discon-
tinued and restarted 3 weeks after the platelet count
recovered. Two patients developed mild hypertension,
most probably related to BVZ that was treated with
oral antihypertensives. There were no side effects
related to the use of the somatostatin analogue.
All patients had elevated CgA levels before
initiation of treatment. Of the 14 evaluable patients,
57% (8/14) had a 50–100% drop, 35% (5/14) had a
25–50% drop or !25% increase and 7% (1/14) had
increase in CgA levels.
Radiological responses included one (7%) complete
response (CR), eight (57%) partial responses (PRs),
three (21%) stable diseases (SDs) and two (14%)
progressive diseases (PDs). Fifty-seven per cent (8/14)
of patients achieved a PR after a median of 12.5 (range
8–20) cycles. Two of these patients completed 12 and
16 cycles, respectively, and their best radiological
responses are shown in Fig. 1. Three (21.5%) patients
had prolonged periods of SD; no radiological change
was detected over a median of 12.6 (range 11–15)
cycles. Two (14%) patients had PD after the fourth and
sixth cycles and discontinued their treatment. In
evaluable patients, the median TTP was 36 weeks
(range 10–60 weeks, mean 33.50, S.D. 14.37, 95%
conﬁdence intervalZ25.2–41.8). In our cohort of
patients, only ﬁve had tumour with Ki-67 O6%. Of
these, one had PD (lung), three had SD and only one
had a PR as described in the ﬁrst case above.
During the past 4 years, there have been six reports
showing activity of TMZ in patients with advanced
NETs. These included a monotherapy protocol
(Ekeblad et al. 2007), three different combinations of
TMZ with BVZ (Kulke et al. 2006a), thalidomide
(Kulke et al. 2006b) and everolimus (Kulke et al.2010)
and two reports investigating the combination of TMZ
with capecitabine (Strosberg et al. 2011, Welin et al.
2011). However, previous protocols differ from that
used in this study in the TMZ administration schedule,
as in all of these studies, TMZ was administered at a
higher dose for fewer days (Kulke et al. 2006a,b, 2010,
Ekeblad et al. 2007, Strosberg et al. 2011, Welin et al.
2011). Our study, although sample size is small,
supports the use of a continuous daily dose of 100 mg
TMZ as the overall response rate (PR and CR rate) was
64%, compared with previously reported that ranged
between 16 and 45% (Kulke et al. 2006a,b, 2010).
There have been two studies testing TMZ monotherapy
or in combination with capecitabine in advanced
NETs reporting different response rates (70 and
33%; Strosberg et al. 2011, Welin et al.2 0 1 1 ).
This difference could be attributed to the different
Table 1 Patient characteristics and previous treatments
Patient characteristics n (%)
Median age (range) 62.5 (47–78) years
Male 10 (67)
Female 5 (33)
Ki-67: 6–19% 5 (33)
Ki-67: 2–5% 10 (67)
Functioning NETs 4 (27)
Non-functioning NETs 11 (73)
Site of origin
Pancreas 7 (47)
Small intestine 3 (20)
Duodenum 1 (7)
Stomach 1 (7)
Rectum 1 (7)
Lung 1 (7)
Unknown 1 (7)
Stage (AJCC 7th edn)
IIIA and B 1 (7)
IV (Liver) 12 (80)
IV (other distant organs) 2 (13)
Treatments before initiation of
TeBeSa
Surgery 6 (40)
Debulking 5 (33)
Whipple 1 (7)
Radiolabelled peptides 2 (13)
Chemotherapy 12 (80)
Platinum based 8 (53)
Streptozotocin/5-ﬂuorouracil 6 (40)
Anthracycline 1 (7)
Docetaxel 1 (7)
Other medical therapies
Interferon 1 (7)
Octreotide long-acting release 100 (15)
Everolimus 7 (1)
Lines of medical therapies
1 10 (67)
2 4 (28)
3 1 (7)
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studies as well as to the fact that in the ﬁrst study
patients were chemotherapy naive. In our study, 80%
of patients were previously treated with chemotherapy.
Although we did not examine MGMT expression, the
high percentage of responses observed is in accordance
with an earlier observation, suggesting that protracted
administration of TMZ even leads to signiﬁcant and
prolonged depletion of MGMT activity (Tolcher et al.
2003). However, a recent retrospective study on
patients with advanced NETs receiving TMZ
suggested that MGMT methylation status did not
correlate with clinical responses (Welin et al. 2011). In
our small cohort of patients, therapeutic responses
were accompanied by a grade III vomiting and mild
myelosuppression that were manageable compared to
previous studies, which reported grade III–IV myelo-
suppression (Kulke et al. 2006b, Ekeblad et al. 2007).
In studies thus far, the majority of responses to
chemotherapy, including TMZ, have been observed in
pancreatic NETs (Kulke et al. 2006a,b, Ekeblad et al.
2007, Modlin et al. 2008, Strosberg et al. 2011, Welin
et al. 2011). Although our study has limitations such as
the heterogeneity of tumour subtypes and the small
number of patients included (Kulke et al. 2011), it
supports the investigation of metronomic TMZ
chemotherapy in pancreatic and non-pancreatic
NETs. It has previously been suggested that NETs
with Ki-67 LI more than 10% maybe responsive to
chemotherapy at an earlier line compared with NETs
with Ki-67 LI !5% that are preferably treated with
biological therapies (Oberg 2002). Although our study
is small, it showed that tumours with Ki-67 LI 2–5 and
6–19% have similar response rates to TeBeSa therapy,
and overall, this is one of the highest reported rates of
single-agent cytotoxics in the literature.
In conclusion, our study suggests that a protracted
daily low dose of TMZ together with BVZ and
octreotide LAR has activity in advanced, grade II
NETs. It is clinically important to explore this
combination in the context of large phase II–III
studies, including translational studies, investigating
the molecular basis of the observed responses and
possible biomarkers.
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Figure 1 Downstaging of gastroenteropancreatic tumours
(arrows) after TeBeSa combination therapy. MRI details
shown before treatment (a) and (c) and after six cycles (b) and
(d) for two patients with a pancreatic (a)/(b) and a duodenal
tumour (c)/(d).
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